- Home
- SDGR vs FRNM Comparison
SDGR vs FRNM Comparison
Compare SDGR & FRNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SDGR | FRNM |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SDGR | FRNM |
|---|---|---|
| Price | $29.05 | $15.98 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 741.9K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | N/A |
| Revenue This Year | $0.76 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $9.97 |
| 52 Week High | $31.59 | $17.50 |
Technical Indicators
Market Signals| Indicator | SDGR | FRNM |
|---|---|---|
| Relative Strength Index (RSI) | 70.23 | 57.94 |
| Support Level | $17.58 | $9.97 |
| Resistance Level | N/A | $17.34 |
| Average True Range (ATR) | 2.03 | 0.92 |
| MACD | 0.62 | -0.09 |
| Stochastic Oscillator | 80.41 | 53.23 |
Price Performance
Historical ComparisonAbout SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.